Methylamine

Methylamine

SCHEMBL18979545

CC(C)(C)O[C]=O.CN.F[B-](F)(F)F.F[B-](F)(F)F.F[B-](F)(F)F.[KH]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylamine SCHEMBL20570915 0.97
SCHEMBL1670 0.81
SCHEMBL754334 0.81 TDP1 (0.31)
SCHEMBL9397770 0.78
SCHEMBL27701016 0.78
SCHEMBL28082245 0.78
SCHEMBL28182677 0.78
Bromide SCHEMBL28123900 0.78
SCHEMBL28871555 0.75
SCHEMBL28240029 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11472801-B2 Crystalline forms of a FGFR inhibitor and processes for preparing the same INCYTE CORPORATION (US) 2022-10-18 US claimed
US-20200270245-A1 CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME INCYTE CORPORATION 2020-08-27 US claimed
EP-3630762-A1 CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME Incyte Corporation (US) 2020-04-08 EP claimed
US-20190055237-A1 CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME INCYTE CORPORATION 2019-02-21 US claimed
WO-2018218100-A1 CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME INCYTE CORPORATION (US) 2018-11-29 WO claimed
EP-4692090-A1 TRICYCLIC COMPOUND AS ATR KINASE INHIBITOR Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (CN) 2026-02-11 EP disclosed
EP-4688768-A1 NOVEL METTL3 INHIBITORS AND USE THEREOF IN THERAPY Novalix (FR) 2026-02-11 EP disclosed
CN-119013266-A Novel GSPT compounds and methods of use of novel compounds 百时美施贵宝公司 2024-11-22 CN disclosed
WO-2024200835-A1 NOVEL METTL3 INHIBITORS AND USE THEREOF IN THERAPY NOVALIX (FR) 2024-10-03 WO disclosed
US-20240294498-A1 FACTOR XIIA INHIBITORS LUNAC THERAPEUTICS LTD (GB) 2024-09-05 US disclosed
EP-4347578-A1 FACTOR XIIA INHIBITORS Lunac Therpeutics Ltd (GB) 2024-04-10 EP disclosed
CN-117751112-A Heteroaryl-3-piperidinedione compounds and application thereof 南京明德新药研发有限公司 2024-03-22 CN disclosed
US-20200270245-A1 CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME INCYTE CORPORATION 2020-08-27 US disclosed
US-20200172539-A1 Azalactam Compounds as HPK1 Inhibitors PFIZER INC. (US) 2020-06-04 US disclosed
EP-3630762-A1 CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME Incyte Corporation (US) 2020-04-08 EP disclosed
US-10611762-B2 Crystalline forms of a FGFR inhibitor and processes for preparing the same INCYTE CORPORATION (US) 2020-04-07 US disclosed
US-20190055237-A1 CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME INCYTE CORPORATION 2019-02-21 US disclosed
WO-2018218100-A1 CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME INCYTE CORPORATION (US) 2018-11-29 WO disclosed
US-9839642-B2 Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors MERCK SHARP & DOHME CORP. (US) 2017-12-12 US disclosed
US-20170173035-A1 BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-06-22 US disclosed